

#### 2nd annual EU Big Data Stakeholder Forum 2021

07 December 2021

Session 1: Report on implementation of the HMA-EMA Big Data Task Force priority recommendations - Overview of 2021 deliverables and plan for 2022

Presented by Peter Arlett Head of Data Analytics and Methods Task Force (EMA), Co-chair of HMA-EMA Big Data Steering Group





#### HMA EMA Big Data Task Force vision


"By delivering the vision of a regulatory system able to integrate Big Data into its assessment and decision making, we can support the development of innovated medicines, deliver life-saving treatments to patients more quickly and optimise the safe and effective use of medicines through measurement of a products performance on the market."

Big Data Task Force final report December 2019





#### Big Data: from recommendations to implementation



## Big Data Priority Recommendations










#### HMA-EMA Joint Big Data Steering Group work plan






On track



#### Approach: Enabling the use and establishing the value of Big Data





#### Key achievements in 2021



DARWIN EU Advisory board established

Study of metadata for real-world data - POC for metadata repository

Joint Action Towards the European Health Data Space – TEHDAS

The TEHDAS Joint Action project develops European principles for the secondary use of health data.

**Data standardisation strategy** 

**RWE** use cases developed with EMA committees – Pilots initiated - Learnings initiative workshop

Data science curriculum finalisedSurvey of skills completed

Discussion on Clusters of Excellence - AI workshop - Pre-pilot on raw data analysis completed

ENCEPP RWE methods guide published – Registry studies guideline published

Veterinary Data Strategy

More in the next sessions

#### Stakeholder engagements in 2021

April 2021 - Joint HMA/EMA Workshop on Artificial Intelligence in Medicines Regulation (Rec. 6)

April 2021 - Technical workshop on real-world metadata for regulatory purposes (Rec. 3)

Rec. 9 May 2021 - Data standardisation workshop (Rec. 9)

June 2021 - Workshop on Big Data in the Veterinary Domain (Rec. 11)

June 2021 – 1st meeting of the DARWIN EU Advisory Board (Rec. 1)

July 2021 – 1<sup>st</sup> meeting of the Advisory Group on raw data analysis (Rec. 6)

October 2021 – Real world metadata survey with Industry (Rec. 3)

November 2021 - Learnings initiative workshop (Rec. 5)

More in the next sessions



### Future highlights in 2022

DARWIN EU Coordination Centre appointed – Start conducting pilot studies for decision making



**RWE integration pilots** (EMA committees)

Publish Q&A on data protection

Multi stakeholder forum Big Data

Agreement on Real world Metadata (v.1.0) - Launch of RWD public catalogue

**EU Data quality Framework** v1.0 available -Recommendations to **strengthen data qualification** – **workshops** on data quality and data qualification

**Roll out** of training (Biostatistics, Pharmacoepidemiology, Data science)

International regulators workshop on real-world evidence

Clusters of Excellence paper - Draft guideline on AI in medicines regulation -Workshop on Raw Data in MAAs and Pilot of raw data analysis execution

**International** cooperation **forum** and the **Vet Data Hub** established



Classified as public by the European Medicines Agency

#### Stakeholder engagement in 2022

DARWIN EU methods, processes and transparency (Rec. 1)

EU data quality framework workshop and survey (Rec. 2)

SAWP qualification procedure workshop (Rec. 2)

Metadata and catalogue of studies (e.g. workshops participation, survey...) (Rec. 3)

RWE pilots/studies (Rec. 5)

Pilot on raw data analysis + workshop on submission & analysis of raw data in MAAs (Rec. 6)

Roadmap for RWE guidance (Rec. 7)

Q&A on data protection (Rec. 8)

International regulator workshop (Rec. 9)



#### In 2025... transformation to data-driven regulation

- The use of RWE will have been enabled and its value will have been established across the spectrum of regulatory use cases.
- **DARWIN EU network as part of the EU Health data space** will support better decision-making via its network of expertise, access to data and established analyses.
- Data will be discoverable and of known quality and representativeness allowing choice of optimal data source, enabling regulators to guide development and expertly assess study results
- **EU Network will have knowledge and experience** in data science, methods and analytics to advise companies developing products and to expertly assess application dossiers
- Learning initiative will allow to continue to learn and evolve to address new regulatory needs, including response to any future health crisis.
- Suite of EU and international guidelines and standards available will help industry and regulators develop and supervise medicines
- · Continued full compliance with data protection and ethics of data sharing
- Working with stakeholders to deliver data transformation to support the development and use of better medicines for patients.

# Thank you

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000

